| Literature DB >> 18566421 |
Matthew R Pipeling1, Erin E West, Christine M Osborne, Amanda B Whitlock, Lesia K Dropulic, Matthew H Willett, Michael Forman, Alexandra Valsamakis, Jonathan B Orens, David R Moller, Noah Lechtzin, Stephen A Migueles, Mark Connors, John F McDyer.
Abstract
Acquisition of T cell responses during primary CMV infection in lung transplant recipients (LTRs) appear critical for host defense and allograft durability, with increased mortality in donor+/recipient- (D+R-) individuals. In 15 D+R- LTRs studied, acute primary CMV infection was characterized by viremia in the presence or absence of pneumonitis, with viral loads higher in the lung airways/allograft compared with the blood. A striking influx of CD8+ T cells into the lung airways/allograft was observed, with inversion of the CD4+:CD8+ T cell ratio. De novo CMV-specific CD8+ effector frequencies in response to pooled peptides of pp65 were strikingly higher in lung mononuclear cells compared with the PBMC and predominated over IE1-specific responses and CD4+ effector responses in both compartments. The frequencies of pp65-specific cytokine responses were significantly higher in lung mononuclear cells compared with PBMC and demonstrated marked contraction with long-term persistence of effector memory CD8+ T cells in the lung airways following primary infection. CMV-tetramer+CD8+ T cells from PBMC were CD45RA- during viremia and transitioned to CD45RA+ following resolution. In contrast, CMV-specific CD8+ effectors in the lung airways/allograft maintained a CD45RA- phenotype during transition from acute into chronic infection. Together, these data reveal differential CMV-specific CD8+ effector frequencies, immunodominance, and polyfunctional cytokine responses predominating in the lung airways/allograft compared with the blood during acute primary infection. Moreover, we show intercompartmental phenotypic differences in CMV-specific memory responses during the transition to chronic infection.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18566421 PMCID: PMC2668691 DOI: 10.4049/jimmunol.181.1.546
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422